Patents by Inventor Charles Z. Ding

Charles Z. Ding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTAL FORM OF C-MET INHIBITOR AND SALT FORM THEREOF AND PREPARATION METHOD THEREFOR
    Publication number: 20210238163
    Abstract: Disclosed are a crystal form of a c-MET inhibitor and a salt form thereof and a preparation method therefor. Specifically involved are the compound as shown in formula (I), and a salt form and a crystal form thereof, and also included is the use of the crystal form and the salt form in the preparation of medicines for treating cancers.
    Type: Application
    Filed: April 26, 2019
    Publication date: August 5, 2021
    Applicant: FUJIAN COSUNTER PHARMACEUTICAL CO., LTD.
    Inventors: Xiongbin XU, Gang LI, Ting YAO, Kun WANG, Lihong HU, Charles Z. DING
  • Quinazoline compound for EGFR inhibition
    Patent number: 11040984
    Abstract: Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: June 22, 2021
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Xile Liu, Charles Z. Ding, Shuhui Chen, Lingyun Wu, Lihong Hu, Haiwen Wan
  • Crystal form of estrogen receptor inhibitor and preparation method therefor
    Patent number: 11034653
    Abstract: Disclosed are a crystal form of an estrogen receptor inhibitor and a preparation method therefor, in particular disclosed are a crystal form A of a compound of formula (I) and a preparation method therefor, and the use of the crystal form in the preparation of a drug for treating breast cancer.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: June 15, 2021
    Assignees: LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD., SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.
    Inventors: Huijun He, Jianyu Lu, Weidong Li, Shenyi Shi, Zhijuan Chen, Charles Z. Ding, Lihong Hu, Tie-Lin Wang, Jiaqiang Dong
  • Pyridone-Pyrimidine Derivative Acting As KRASG12C Mutein Inhibitor
    Publication number: 20210147418
    Abstract: Provided are a class of KRAS G12C mutein inhibitors, which relate in particular to a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 27, 2021
    Publication date: May 20, 2021
    Inventors: Yaxian CAI, Zhaobing XU, Hailong YANG, Shiqi HAN, Guoping HU, Lihong HU, Charles Z. DING, Jian LI, Shuhui CHEN
  • Hepatitis B virus surface antigen inhibitor
    Patent number: 11008331
    Abstract: 10-oxo-6,1-dihydrobenzo[e]pyrido[1,2-c][1,3]oxazine-9-carboxylic acid derivatives of formula (I) as hepatitis B surface antigen inhibitors or pharmaceutically acceptable salts thereof, and uses of a compound of formula (I) or pharmaceutically acceptable salts thereof and pharmaceutical compositions thereof in preparation of medicaments for treatment of viral hepatitis B.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: May 18, 2021
    Assignee: FUJIAN COSUNTER PHARMACEUTICAL CO., LTD.
    Inventors: Fei Sun, Jinhua Du, Yanbin Hu, Lili Zhou, Charles Z. Ding, Shuhhui Chen
  • MONOCYCLIC B-LACTAM COMPOUND FOR TREATING BACTERIAL INFECTION
    Publication number: 20210115035
    Abstract: Disclosed are a class of new monocyclic ?-lactam compounds, an isomer thereof or pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the compounds, and the use of same in preparing drugs for treating diseases associated with bacterial infection. Specifically disclosed are the compounds as shown in formula (I?) and formula (II?), isomers thereof or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: January 29, 2019
    Publication date: April 22, 2021
    Inventors: Lianghu GU, Wei LUO, Zhigang HUANG, Charles Z. DING, Cheng LI, Shuhui CHEN
  • SALT SERVING AS AKT INHIBITOR AND CRYSTAL THEREOF
    Publication number: 20210087205
    Abstract: A salt serving as an Akt inhibitor and a crystal thereof, specifically related to a salt of the compound of formula (I) and a crystal thereof.
    Type: Application
    Filed: December 12, 2018
    Publication date: March 25, 2021
    Inventors: Gang LI, Lun LU, Qingqing LU, Lihong HU, Charles Z. DING
  • CRYSTAL FORM AND SALT FORM OF TGF-BRI INHIBITOR AND PREPARATION METHOD THEREFOR
    Publication number: 20210079021
    Abstract: Disclosed in the present invention are a crystal form and salt form of a TGF-?R1 inhibitor and a preparation method therefor, and further disclosed is an application of the crystal form and the salt form in preparation of medicines for treating cancers.
    Type: Application
    Filed: December 13, 2018
    Publication date: March 18, 2021
    Inventors: Lifang WU, Huijun HE, Jianyu LU, Charles Z. DING, Lihong HU, Weidong LI, Shenyi SHI, Jian LI, Shuhui CHEN
  • Salt type and crystal type of 4h-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof
    Patent number: 10941150
    Abstract: Disclosed in the present invention are a salt type and crystal type of 4H-pyrazolo[1, 5-alpha]benzimidazole compound and the preparation method and intermediate thereof. The 4H-pyrazolo[1,5-alpha]benzimidazole compound has the structure of Compound 2.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: March 9, 2021
    Assignees: HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC., HUMANWELL HEALTHCARE (GROUP) CO., LTD.
    Inventors: Xuehai Wang, Charles Z. Ding, Jie Shen, Shuhui Chen, Lie Li, Gang Li, Yong Xu, Cailin Wang, Ronghua Tu, Jimeng Wang, Yang YuE, Biao Deng, Hailiang Chen, Hui Liu, Wenjie Sun, Cong Wang, Lu Huang, Zheng Wang, Weidong Li
  • CRYSTAL FORM OF ß-LACTAMASE INHIBITOR AND PREPARATION METHOD THEREFOR
    Publication number: 20200385385
    Abstract: Disclosed in the present disclosure are a crystal form of a ?-lactamase inhibitor and a preparation method therefor, as well as an application of the crystal form in preparing a ?-lactamase inhibitor drug.
    Type: Application
    Filed: December 3, 2018
    Publication date: December 10, 2020
    Inventors: Cheng LI, Zhigang HUANG, Charles Z. DING, Weidong LI
  • ANTI-HBVTETRAHYDROISOXAZOLO[4,3-C]PYRIDINE COMPOUNDS
    Publication number: 20200377517
    Abstract: Disclosed are a class of anti-HBV tetrahydroisoxazolo[4,3-c]pyridine compounds and pharmaceutically acceptable salts thereof or isomers thereof, the compounds being represented by the formula (I).
    Type: Application
    Filed: November 16, 2018
    Publication date: December 3, 2020
    Inventors: Lifang WU, Fei SUN, Jinhua DU, Charles Z. DING, Shuhui CHEN, Xiquan ZHANG, Hongjiang XU, Ling YANG
  • M-dihydroxybenzene derivative crystal and salt, and manufacturing method thereof
    Patent number: 10851071
    Abstract: Provided are a crystal and salt of an m-dihydroxybenzene derivative represented by formula (I), a manufacturing method thereof, and an application of the crystal in preparing a pharmaceutical product for treating a HSP90-mediated disease.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: December 1, 2020
    Assignee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Inventors: Xiaobing Yan, Wei Huang, Dan Li, Charles Z. Ding, Fei Liu, Xiquan Zhang
  • Indolo substituted piperidine compound as estrogen receptor down-regulator
    Patent number: 10774081
    Abstract: Disclosed in the present invention is a type of indole substituted piperidine compounds as an estrogen receptor down-regulator. Specifically disclosed are a compound as shown in formula (I), a pharmaceutically acceptable salt, hydrate or prodrug thereof, a preparation method therefor, a pharmaceutical composition thereof, and a use thereof as an estrogen receptor down-regulator in the treatment of estrogen receptor positive breast cancers.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: September 15, 2020
    Assignees: LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD., SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.
    Inventors: Jianyu Lu, Charles Z. Ding, Xu Zeng, Huijun He, Shuhui Chen, Lihong Hu, Jiaqiang Dong, Tie-Lin Wang
  • ?-lactamase inhibitors
    Patent number: 10738051
    Abstract: Disclosed in the present invention is a type of novel ?-lactamase inhibitors, and specifically disclosed are a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: August 11, 2020
    Assignee: QILU PHARMACEUTICAL CO., LTD.
    Inventors: Boyu Hu, Charles Z. Ding, Zhigang Huang, Ruibin Lin, Minliang Xiao, Jinsheng Xie, Shuhui Chen, Cheng Li
  • CRYSTAL FORM OF ESTROGEN RECEPTOR INHIBITOR AND PREPARATION METHOD THEREFOR
    Publication number: 20200247748
    Abstract: Disclosed are a crystal form of an estrogen receptor inhibitor and a preparation method therefor, in particular disclosed are a crystal form A of a compound of formula (I) and a preparation method therefor, and the use of the crystal form in the preparation of a drug for treating breast cancer.
    Type: Application
    Filed: September 25, 2018
    Publication date: August 6, 2020
    Inventors: Huijun HE, Jianyu LU, Weidong LI, Shenyi SHI, Zhijuan CHEN, Charles Z. DING, Lihong HU, Tie-Lin WANG, Jiaqiang DONG
  • Aryl-Phosphorus-Oxygen Compound As EGFR Kinase Inhibitor
    Publication number: 20200207768
    Abstract: Disclosed is a class of new aryl-phosphorus-oxygen compounds as shown in formula (I) as EGFR kinase inhibitors, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: July 19, 2018
    Publication date: July 2, 2020
    Inventors: Lingyun WU, Xile LIU, Charles Z. DING, Shuhui CHEN, Lihong HU, Lele ZHAO, Wei PAN, Guoping HU, Jian LI, Ning ZHAO, Jun ZHAO
  • HEPATITIS B VIRUS SURFACE ANTIGEN INHIBITOR
    Publication number: 20200197409
    Abstract: Disclosed in the present invention is a new 11-oxo-7,11-dihydro-6h-benzo-[f]pyrido[1,2-d][1,4]azepine oxepin-10-carboxylic acid derivative serving as a hepatitis B virus surface antigen inhibitor. Specifically disclosed are a compound represented by formula (V) or a pharmaceutically acceptable salt thereof, and applications of the compound represented by formula (V) or the pharmaceutically acceptable salt thereof and a pharmaceutical composition thereof in the treatment of viral hepatitis B.
    Type: Application
    Filed: May 22, 2018
    Publication date: June 25, 2020
    Applicants: FUJIAN COSUNTER PHARMACEUTICAL CO., LTD., MEDSHINE DISCOVERY INC.
    Inventors: Charles Z. DING, Fei SUN, Yanbin HU, Shuhui CHEN
  • QUINAZOLINE COMPOUND FOR EGFR INHIBITION
    Publication number: 20200190107
    Abstract: Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.
    Type: Application
    Filed: December 29, 2017
    Publication date: June 18, 2020
    Inventors: Xile LIU, Charles Z. DING, Shuhui CHEN, Lingyun WU, Lihong HU, Haiwen WAN
  • 1,6-naphthyridine derivatives as CDK4/6 inhibitor
    Patent number: 10676474
    Abstract: Disclosed is a series of compounds acting as CDK4/6 inhibitors. Specifically disclosed are compounds as represented by formula (I), pharmaceutically acceptable salts or isomers thereof, pharmaceutical compositions containing same, and the use thereof in the preparation of drugs for treating cancers.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: June 9, 2020
    Assignees: CSTONE PHARMACEUTICALS, MEDSHINE DISCOVERY INC.
    Inventors: Zhaobing Xu, Lihong Hu, Charles Z. Ding, Shuhui Chen
  • Dihydropyrazole azepine compound serving as Akt inhibitor
    Patent number: 10654868
    Abstract: Provided is a dihydropyrazole azepine compound serving as an Akt inhibitor; specifically disclosed is a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: May 19, 2020
    Assignee: HARBIN ZHENBAO PHARMACEUTICAL CO., LTD.
    Inventors: Lun Lu, Zhibo Zhang, Gang Li, Lihong Hu, Charles Z. Ding, Shuhui Chen